Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1471-2407
Extent
Online-Ressource
Language
Englisch
Notes
online resource.

Bibliographic citation
Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia ; volume:18 ; number:1 ; day:15 ; month:11 ; year:2018 ; pages:1-5 ; date:12.2018
BMC cancer ; 18, Heft 1 (15.11.2018), 1-5, 12.2018

Creator
Bertamini, Luca
Nanni, Jacopo
Marconi, Giovanni
Abbenante, Mariachiara
Robustelli, Valentina
Bacci, Francesco
Matti, Antonella
Paolini, Stefania
Sartor, Chiara
Monaco, Silvia Lo
Fontana, Maria Chiara
De Polo, Stefano
Cavo, Michele
Curti, Antonio
Martinelli, Giovanni
Papayannidis, Cristina
Contributor
SpringerLink (Online service)

DOI
10.1186/s12885-018-5026-x
URN
urn:nbn:de:101:1-2018121519404329719011
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
14.08.2025, 11:01 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Bertamini, Luca
  • Nanni, Jacopo
  • Marconi, Giovanni
  • Abbenante, Mariachiara
  • Robustelli, Valentina
  • Bacci, Francesco
  • Matti, Antonella
  • Paolini, Stefania
  • Sartor, Chiara
  • Monaco, Silvia Lo
  • Fontana, Maria Chiara
  • De Polo, Stefano
  • Cavo, Michele
  • Curti, Antonio
  • Martinelli, Giovanni
  • Papayannidis, Cristina
  • SpringerLink (Online service)

Other Objects (12)

Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia

Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia

Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia

Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia

Carfilzomib based treatment strategies in the management of relapsed/refractory multiple myeloma with extramedullary disease

Carfilzomib based treatment strategies in the management of relapsed/refractory multiple myeloma with extramedullary disease

Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease

Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease

Treatment of Adult Patients with Relapsed/Refractory B-Cell Philadelphia-Negative Acute Lymphoblastic Leukemia

Treatment of Adult Patients with Relapsed/Refractory B-Cell Philadelphia-Negative Acute Lymphoblastic Leukemia

Population pharmacokinetics of inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma

Population pharmacokinetics of inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia

Survival after blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia

Survival after blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia

Management of relapsed-refractory diffuse large B cell lymphoma

Management of relapsed-refractory diffuse large B cell lymphoma

Matching-Adjusted Indirect Comparison of Blinatumomab vs. Inotuzumab Ozogamicin for Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia

Matching-Adjusted Indirect Comparison of Blinatumomab vs. Inotuzumab Ozogamicin for Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia

Benefit–Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

Benefit–Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma

Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma

Related objects